Completed PHASE1 INTERVENTIONAL 1-arm NCT00284908

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Sponsor: STEBA France

Conditions Duodenal Ulcer Esophagitis Gastroesophageal Reflux Stomach Ulcer

Interventions S-Tenatoprazole-Na (STU-Na)

Updated 6 times since 2017 Last updated: Mar 21, 2008 Started: Sep 30, 2006 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Duodenal Ulcer and Esophagitis, this trial is completed. The trial is conducted by STEBA France and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

STEBA France
STEBA LABORATORIES LTD.

Data source: STEBA France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States